Table 1.
Clinicopathological characteristics of 86 EGFR-mutated patients treated with pembrolizumab.
| Characteristics | Number | Percent (%) |
|---|---|---|
| Age(median age, Range) | 62(39-80) | – |
| Sex | ||
| Male | 48 | 55.8% |
| Female | 38 | 44.2% |
| Smoking history | ||
| Yes | 41 | 47.7% |
| No | 45 | 52.3% |
| Recurrence after surgery | ||
| Yes | 39 | 45.3% |
| No | 47 | 54.7% |
| Treatment line of PD-1 Inhibitors | ||
| Second line | 4 | 4.7% |
| Third or after line | 82 | 95.3% |
| Brain metastasis | ||
| Yes | 17 | 19.8% |
| No | 69 | 80.2% |
| PD-L1 TPS | ||
| <1% | 17 | 19.8% |
| 1~49% | 32 | 37.2% |
| ≥50% | 26 | 30.2% |
| Unknown | 11 | 12.8% |
| EGFR mutation subtype | ||
| 19del | 22 | 25.6% |
| 21L858R | 47 | 54.6% |
| T790M | 8 | 9.3% |
| Other | 9 | 10.5% |
| Treatment | ||
| PM | 32 | 37.2% |
| P+C | 26 | 30.2% |
| P+A | 28 | 32.6% |